Cardioxane

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status
European Commission final decision

Overview

Questions and answers on Cardioxane (dexrazoxane, powder for solution for injection, 500 mg)

Outcome of a procedure under Article 13 of Regulation (EC) No 1234/2008

On 18 May 2017, the European Medicines Agency completed an arbitration procedure for Cardioxane (dexrazoxane powder for solution for injection). The Agency had been asked to arbitrate on the removal of the contraindication for children and adolescents treated with high cumulative doses of cancer medicines called anthracyclines. Its Committee for Medicinal Products for Human Use (CHMP) concluded that such a removal is acceptable. The contraindication should however remain in children and adolescents who are given lower cumulative doses of anthracyclines.

Key facts

About this medicine
Approved name
Cardioxane
International non-proprietary name (INN) or common name
dexrazoxane
About this procedure
Current status
European Commission final decision
Reference number
EMEA/H/A-13/1453
Type
Article 13 referrals

This type of referral is triggered for a medicine that has been authorised by mutual recognition or via the decentralised procedure when there is disagreement between Member States on a variation (type II), on the grounds of a potential serious risk to public health.

Key dates and outcomes
CHMP opinion date
19/07/2017
EC decision date
19/07/2017

All documents

Opinion provided by Committee for Medicinal Products for Human Use

  • List item

    Cardioxane Article 13 referral - Questions and answers on Cardioxane (dexrazoxane, powder for solution for injection, 500 mg) (PDF/77.7 KB)


    First published: 19/05/2017
    Last updated: 26/07/2017
    EMA/184071/2017

  • List item

    Cardioxane Article 13 referral - Annex III (PDF/24.46 KB)


    First published: 19/05/2017
    Last updated: 26/07/2017

  • European Commission final decision

  • List item

    Cardioxane Article 13 referral - CHMP assessment report (PDF/184.43 KB)


    First published: 26/07/2017
    Last updated: 26/07/2017

  • List item

    Cardioxane Article 13 referral - Annex I (PDF/35.55 KB)


    First published: 26/07/2017
    Last updated: 26/07/2017

  • List item

    Cardioxane Article 13 referral - Annex II (PDF/37.02 KB)


    First published: 26/07/2017
    Last updated: 26/07/2017

  • Description of documents published

    Please note that some of the listed documents apply only to certain procedures.

    • Overview - lay-language summary of the stage of the procedure
    • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
    • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
    • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
    • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
    • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
    • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
    • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
    • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
    • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
    • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
    • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
    • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
    • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
    • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

    Note that older documents may have different titles.

    News

    How useful was this page?

    Add your rating
    Average
    1 rating